secwatch.observer — SEC 8-K summary
======================================

Issuer:     Organon & Co. (OGN)
CIK:        0001821825
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0001104659-22-114226
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Organon Q3 revenues $1.54B (-4% YoY); raises FY adjusted EBITDA margin guidance
-------------------------------------------------------------------------------

- Q3 revenue $1,537M, down 4% YoY as-reported but up 3% ex-FX.
- GAAP diluted EPS $0.89, non-GAAP adjusted diluted EPS $1.32.
- Women's Health revenue grew 19% (23% ex-FX) on Nexplanon demand.
- Full year 2022 revenue guidance narrowed to $6.1-$6.2B; adjusted EBITDA margin raised to 33.5%-34.5%.
- Board declares quarterly dividend of $0.28 per share.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1821825/000110465922114226/0001104659-22-114226-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1821825/000110465922114226/tm2229543d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-114226

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer